Table 6 Logistic regression of dose escalation status and treatment year adjusting for potential confounders of the NCDB cohort with RT dose exclusions during Period 2 (2010–2012)
NCDB 2010–2012 (N = 6546) | ||||
|---|---|---|---|---|
Study sample characteristics | Escalated dose | Standard dose | Escalated vs standard dose | |
No. (%) | No. (%) | Adjusted OR (95% CI) | P* | |
Treatment year | 0.77 (0.69–0.85) | <0.0001 | ||
Age | ||||
≤ 67 yo | 367 (54) | 3124 (53) | ref | |
> 67 yo | 308 (46) | 2747 (47) | 0.93 (0.79–1.09) | 0.38 |
Sex | ||||
Male | 393 (58) | 3308 (56) | ref | |
Female | 282 (42) | 2563 (44) | 0.94 (0.79–1.11) | 0.45 |
Race | ||||
White | 594 (88) | 4937 (84) | ref | |
Non-white | 78 (12) | 895 (15) | 0.76 (0.59–0.98) | 0.04 |
Missing | 3 (<1) | 39 (1) | Not included | |
Histology | ||||
Squamous | 315 (47) | 2658 (45) | ref | |
Non-Squamous | 360 (53) | 3213 (55) | 0.97 (0.82–1.14) | 0.72 |
Derived AJCC v6 T-stage | ||||
T0-2 | 425 (63) | 3693 (63) | ref | |
T3 | 250 (37) | 2178 (37) | 1.01 (0.85–1.19) | 0.95 |
Charlson/Deyo Score | ||||
0 | 406 (60) | 3510 (60) | ref | 0.80 |
1 | 196 (29) | 1684 (29) | 1.00 (0.83–1.20) | 0.83 |
2+ | 73 (11) | 677 (11) | 0.96 (0.73–1.24) | |
Hospital typea | ||||
Community | 520 (77) | 4220 (72) | ref | |
Academic | 155 (23) | 1651 (28) | 0.80 (0.66–0.97) | 0.02 |
Hospital settinga | ||||
Metro | 495 (73) | 4421 (75) | ref | |
Non-metro | 163 (24) | 1285 (22) | 1.07 (0.88–1.29) | 0.51 |
Missing | 17 (3) | 165 (3) | Not included | |